VIAVI Wins U.S. Army Test Range Contract; Positive but Not Enough to Alter Sell Thesis

What happened

The U.S. Army's Threat Systems Management Office selected VIAVI's T/Rx software-defined transceiver for electromagnetic spectrum environments at newly opened test ranges, supporting drone and counter-drone development. This win underscores VIAVI's growing aerospace and defense exposure, which was already a stated growth driver in recent quarters, with NSE segment up 35.5% year-over-year in Q1 FY26. However, the contract's financial magnitude is undisclosed, and it comes amid a stretched valuation of ~304x trailing EPS and ~37x EV/EBITDA, with net debt/EBITDA at 2.05 and interest coverage of only 2.87. The DeepValue master report rates VIAVI a Strong Sell, citing customer concentration, pricing pressure, and high leverage, noting the stock has risen 94% over the past year and now embeds aggressive assumptions for flawless Spirent integration and sustained AI/data-center growth. While this defense win adds a positive incremental catalyst, it does not address the core concerns of balance-sheet risk and valuation, leaving the risk/reward skewed to the downside over the next 6–18 months.

Implication

Investors should treat this news as a modest incremental positive for VIAVI's aerospace/defense effort, but it does not alter the fundamental risk of owning a highly leveraged, premium-valued stock. The contract's size is unknown and may not move the needle on revenue, while the stock trades at ~304x earnings with net debt/EBITDA above 2x and interest coverage below 3x. Additional defense wins could help sentiment, but the core bull case still relies on flawless Spirent integration and sustained hyperscaler spending, both of which carry execution risk. Given the 94% 12-month gain and crowded positioning, any disappointment could trigger sharp multiple compression. We maintain a sell bias for new capital and would use strength to reduce exposure.

Thesis delta

The Army T/Rx selection is a positive but unquantified incremental for VIAVI's defense exposure, consistent with existing tailwinds cited in the DeepValue report. It does not address the primary concerns of stretched valuation (~304x P/E), elevated leverage (net debt/EBITDA 2.05, interest coverage 2.87), or execution risk on Spirent. Therefore, the Strong Sell thesis remains unchanged.